Mavenclad can be prescribed at general hospitals

Passed DC of SMC, AMC, and Severance Hospitals

Expected to improve convenience

New multiple sclerosis drug Mavenclad can be prescribed in general hospitals According to related industries, highly active recurrent multiple sclerosis treatment Mavenclad (Cladribine) by Merck has now passed the drug commitee (DC) of SMC, AMC, Shinchon Severance Hospital, and NCC.

 

Mavenclad is the first short-term oral treatment that has shown a significant overall effect in terms of the degree of physical disability progression, annual recurrence rate, number of active lesions shown on MRI, and major disease activity indicators in patients with recurrent multiple sclerosis.

 

Mavenclad's clinical trial program included long-term follow-up data from the 8-year prospective observational registry PREMIERE study, along with the CLARITY Phase 3 study and CLARITY EXTENSION, ORACLE MS, and ONWARD Phase 2 study corresponding to the CLARITY expanded clinical trial.

 

As a result of post-hoc analysis of patients with high disease activity in the CLARITY 2,3 study conducted for two years, the annual recurrence rate of patients receiving Mavenclad decreased by 67%, and the Extended Disability Status Scale (EDSS), which indicates the degree of disability progression.

 

Also, Mavenclad administration group showed a 82% decrease compared to the control group.

 

However, Mavenclad’s significant adverse reactions are lymphopenia and shingles.

 

The lymphocyte count of patients must be measured before and during Mavenclad administration to patients with multiple sclerosis.

 

It is contraindicated in certain populations, including patients with impaired immune function and pregnant women.

 

Seongmin Kim, Professor of Neurology, SNUH said, "Multiple sclerosis is a chronic inflammatory demyelinating disease that occurs in the central nervous system such as the brain and spinal cord.

 

If not treated, symptoms may worsen and sequelae such as severe disorders may remain, so a new treatment option with high convenience is available.

 

It was a necessary situation.

 

Mavenclad can be taken orally and can help improve the quality of life for patients in that it provides lasting effects for 4 years with only short-term treatment of up to 20 days."